retatrutide nejm phase 2 obesity 2023 jastreboff Half-Life & Pharmacokinetics: 6-Day Decay Curve Retatrutide is getting attention — – First Retatrutide phase 3 data,

Hershey Medical Center with 60 adults (ages 30-79): 250 mg or 1,000 mg daily for 6-7 months Whole Blood: 30% increase Red Blood Cells: 35% increase Buccal Cells: 260% increase Taking 1,000 mg daily significantly boosts antioxidants, promoting better health and a stronger immune system

The FDA-approved prescribing information for semaglutide and tirzepatide does not list HRT as a contraindication, and no direct pharmacological interaction between these medication classes has been established in clinical trials

In clinical trials, patients using tirzepatide reported an average weight loss of up to 20% of their body weight over a year

News & Publications Supplementation with essential phospholipids lowered liver-fat markers in fatty liver disease

Shungus study is expected to run through 2025 and is still open